Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1012 in Relapsed/Refractory AML
NCT05471323Phase 1Unknown
- Sponsor
- Guangdong Ruishun Biotechnology Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RC1012 in acute myeloid leukemia (AML), sponsored by Guangdong Ruishun Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity up to 28 days, Maximum Tolerated Dose up to 28 days and 1 more. Status: unknown.
02
Drugs
RC1012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05471323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471323.